Press releases
- Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds
- Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)
- Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity
- Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
- Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024
- Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
- Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
More ▼
Key statistics
As of last trade, Palatin Technologies Inc (0KF3:LSE) traded at 1.75, 20.03% above the 52 week low of 1.46 set on Sep 28, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 1.75 |
Low | 1.75 |
Bid | -- |
Offer | -- |
Previous close | 1.75 |
Average volume | 681.33 |
---|---|
Shares outstanding | 16.14m |
Free float | 15.18m |
P/E (TTM) | -- |
Market cap | 27.27m USD |
EPS (TTM) | -2.39 USD |
Data delayed at least 20 minutes, as of Jul 22 2024 14:41 BST.
More ▼